Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Targeted Oncology|June 21, 2015
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-AnalysisGaetan Des Guetz, Thierry Landre, Bernard Uzzan, et al.
Journal of Geriatric Oncology|September 13, 2015
Measurement of gait speed in older adults to identify complications associated with frailty: A systematic reviewFrederic Pamoukdjian, Elena Paillaud, Laurent Zelek, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2020
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutationThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
JTO Clinical and Research Reports|June 15, 2026
Brief Report: Real-World Comparative Effectiveness of First-Line Immune Checkpoint Inhibitor Monotherapy Versus Chemo-Immunotherapy in Metastatic NSCLC With PD-L1 More Than or Equal to 50%: A Meta-AnalysisThierry Landre, Jean-Baptiste Assié, Kader Chouahnia, et al.
International Journal of Colorectal Disease|April 23, 2018
Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patientsThierry Landre, Emilie Maillard, Chérifa Taleb, et al.
Expert Review of Anticancer Therapy|May 30, 2024
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trialsThierry Landre, Jean-Baptiste Assié, Kader Chouahnia, et al.
Cancer Immunology, Immunotherapy : CII|August 11, 2021
Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trialsThierry Landre, Gregoire Justeau, Jean-Baptiste Assié, et al.
American Journal of Clinical Oncology|December 17, 2015
Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6Marie Laurent, Gaétan Des Guetz, Sylvie Bastuji-Garin, et al.
Journal of Geriatric Oncology|February 21, 2015
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)Gaetan Des Guetz, Thierry Landre, Virginie Westeel, et al.
Pageof 2